The symposium will be presented in a live case-based format designed specifically to reinforce key learning objectives and engage attendees in an interactive discussion. The program will take place at The Conrad Hotel in Indianapolis, Indiana on March 6, 2010.

Statement of Need
Despite recent gains made in the management of hematologic malignancies and disorders, the treatment of these diseases remains a challenge for many healthcare professionals and patients. Formulating which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise, and available health-system resources. While difficult, these decisions require knowledge of current clinical and experimental data in order for the appropriate integration of novel therapeutic agents and strategies into clinical practice. As recently the development of novel treatment approaches have reached the clinic and have increased therapeutic options available for patients with hematologic malignancies and disorders, the future of clinical medicine within hematologic malignancies and disorders will undoubtedly come to rely more on novel agents and combinations. This educational program will provide clinicians the tools necessary to interpret clinical trial data regarding these agents, including novel combinations, and their potential place in therapy. In addition, this innovative education activity will provide the practicing hematologist/oncologist and healthcare professionals caring for patients with hematologic malignancies with the most up-to-date clinical, experimental, and safety information on the emerging hematology treatment approaches.

Who Should Attend?
The target audience for St. Vincent’s 7th Annual INDY Hematology Review includes hematology and oncology professionals, and registered nurses treating hematologic malignancies and disorders.

Learning Objectives – Physicians and Pharmacists
Upon completion of this educational activity, participants should be better able to:

• Implement the most clinically effective management strategies for the various types and stages of lymphoma, leukemia, and multiple myeloma to improve patient care
• Discuss the current data and evolving developments related to the treatment of the different types of leukemia and myelodysplastic disorders with regards to both efficacy and toxicity, and how to best integrate these advances into patient care
• Understand the primary and secondary treatment approaches for T-cell leukemias and lymphomas
• Evaluate treatment advancements in the management of disorders of platelets, red blood cells, and neutrophils
• Apply autologous and allogeneic stem cell transplantation optimally in the treatment of hematologic malignancies to induce durable remissions and increase patient survival
• Analyze the safety and efficacy of novel agents under investigation for the treatment of myeloproliferative disorders
• Describe new developments in the treatment of paroxysmal nocturnal hemoglobinuria

Learning Objectives – Nurses
After completing this activity, the participant should be better able to:

• Implement the most clinically effective management strategies for the various types and stages of lymphoma, leukemia, and multiple myeloma to improve patient care
• Discuss the current data and evolving developments related to the treatment of the different types of leukemia and myelodysplastic disorders with regards to both efficacy and toxicity
• Describe how to best integrate evolving advances into patient care
• Recognize the primary and secondary treatment approaches for T-cell leukemias and lymphomas
• Evaluate treatment advancements in the management of disorders of platelets, red blood cells, and neutrophils
• Apply autologous and allogeneic stem cell transplantation optimally in the treatment of hematologic malignancies to induce durable remissions and increase patient survival
• Analyze the safety and efficacy of novel agents under investigation for the treatment of myeloproliferative disorders
• Describe new developments in the treatment of paroxysmal nocturnal hemoglobinuria